| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | EVP, Chief Commercial Officer | SVP, Chief Commercial Officer
2 companies
Alexander Cumbo is President and CEO at SLDB and has filed Form 4s across 2 companies. Alexander Cumbo's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.6M at current prices.
Historically, Alexander Cumbo's trades have earned a below-average insider score of 34/100 across 7 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -34.8%.
The biggest single holding is SLDB (~$1.5M) as President and CEO. The SLDB filings lean toward selling, a net 190,859 shares.
Alexander Cumbo has 32 Form 4 filings on record from March 2017 to September 2026, across 5 companies: Director at Stoke Therapeutics (STOK), 2026; Director at Vor Biopharma (VOR), 2025–2026; Director at Climb Bio (CLYM), 2025–2026, and 2 more.
The 71 reported transactions were 22 option or other derivative awards, 22 option exercises, 15 open-market sales and 8 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 11 sales worth about $13.4M.
The largest open-market sale was 42,000 shares of SRPT at an average $125.50 on December 13, 2019, about $5.3M.
5 of the 7 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 2 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | SLDB Solid Biosciences Inc. | President and CEO | Sale+OE10b5-1 | 16,644 | $5.82 | $96,923.01 | -6.6% | +2.7% | - | |
| Feb 4, 2026 | SLDB Solid Biosciences Inc. | President and CEO | Sell10b5-1 | 48,913 | $6.44 | $315,092.65 | -18.1% | +5.8% | - | |
| Feb 2, 2026 | SLDB Solid Biosciences Inc. | President and CEO | Sale+OE10b5-1 | 80,258 | $6.44 | $516,612.72 | -22.9% | +12.4% | - | |
| Dec 3, 2025 | SLDB Solid Biosciences Inc. | President and CEO | Sale+OE10b5-1 | 10,808 | $5.11 | $55,228.88 | -11.7% | +15.0% | - | |
| Feb 14, 2025 | SLDB Solid Biosciences Inc. | President and CEO | Sale+OE10b5-1 | 11,365 | $3.96 | $45,005.40 | -15.8% | -35.7% | +53.6% | |
| Dec 3, 2024 | SLDB Solid Biosciences Inc. | President and CEO | Sale+OE | 11,114 | $5.60 | $62,236.18 | -22.4% | -1.2% | +0.2% | |
| Dec 4, 2023 | SLDB Solid Biosciences Inc. | President and CEO | Sale+OE | 11,757 | $2.77 | $32,516.33 | -40.3% | +181.7% | +50.6% | |
| Dec 13, 2019 | SRPT Sarepta Therapeutics, Inc. | EVP, Chief Commercial Officer | Sale+OE | 42,000 | $125.50 | $5,271,000.00 | -95.7% | - | - | |
| Feb 1, 2019 | SRPT Sarepta Therapeutics, Inc. | SVP, Chief Commercial Officer | Sale+OE | 15,000 | $140.00 | $2,100,000.00 | -49.6% | - | - | |
| Jul 9, 2018 | SRPT Sarepta Therapeutics, Inc. | SVP, Chief Commercial Officer | Sale+OE | 33,782 | $137.32 | $4,638,944.24 | -54.0% | - | - |